Come up with a name for your new list and we'll add to it:
TyrNovo raised a round of funding on January 12, 2017. Investors include
Kitov Pharmaceuticals Holdings.
TyrNovo is a developer of novel small molecules in the immuno-oncology therapeutic field, including NT219, a small molecule which has displayed potent anti-tumor effects and increased survival in vari…